TeleCervicography(cervical magnification imaging and reading system)
What is cervical cancer?
- Cervical cancer is a female cancer that occurs in the cervix and is a typical female cancer that kills more than 300,000 people every year
- Having the second-highest death rate among female cancers in the world, more than 80% of deaths due to it occur in underdeveloped countries with insufficient medical infrastructure
- The main cause of it is HPV(Human Papilloma Virus), and more than 80% of women are infected more than once in their lifetime, but most of it naturally disappears or can be treated after early detection.
- If left unattended, it can slowly develop into cervical cancer over 5 to 10 years without observable symptoms, so early examination and screening tests are important.
Limitation of current screening
The traditional methods such as Cytology, HPV, and VIA tests have limitations in both screening and triage, Pap smear and HPV tests, despite its popularity, have shown drawbacks in reliability and accuracy. VIA test is highly dependent on skill and experience of the test provider.
Infrastructure
Need a diagnostic laboratory and infrastructure
Low sensitivity
Pap smear and HPV test are not sufficient
It takes time
Up to 7days to get a result it leads to miss follow-up
Screening for early detection is the solution,
CerviCARE AI brings the solution!!
CerviCARE® Al provides an effective measure to screen cervical cancer. The Integrated deep learning artificial intelligence predicts findings from cervix just like how experienced gynecologic oncologists would determine.
Cervicography(cervical magnification imaging and reading system)
Normal
Atypical
Dysplasia (precancer stage)
Cervical cancer
- Complements the low sensitivity and high false negative rate of the Pap smear test
- Reads, after magnified imaging, cervical lesions that are difficult to identify by VIA (Visual Inspection with Acetic Acid)
- It is possible to image on-site and request remote reading without the need for medical infrastructure
- Accurate reading and transmission of its results by a gynecological cancer specialist
High image quality
Reproduction of actual cervical images with the best closeup imaging
Strengthened information protection
Image loss prevention and backup function enhancement
2.4Ghz, 5Ghz wifi
Supports fast transmission speeds and reliable network services
Simple interface
Improved UI/UX design so that everyone can easily use it
Touch Screen
Provides an intuitive use environment with LCD touch
Ergonomic design
Ergonomic design makes it light and easy to use
High image quality
Reproduction of actual cervical images with the best closeup imaging
Strengthened information protection
Image loss prevention and backup function enhancement
2.4Ghz, 5Ghz wifi
Supports fast transmission speeds and reliable network services
Simple interface
Improved UI/UX design so that everyone can easily use it
Touch Screen
Provides an intuitive use environment with LCD touch
Ergonomic design
Ergonomic design makes it light and easy to use
TeleCervicography Platform
TeleCervicography Reading specialist group
[ Korea TeleCervicography Research Society ]
- Obtained reading qualification and license from the Medical College of Wisconsin in the United States.
- It consists of 40 professors of gynecologic oncology at 32 university hospitals in Korea.
- Have held regular seminars and academic exchanges for more than 25 years
Development of CerviCARE® AI
1996
Analogue system
- Introduced a U.S. off-line Cervicography(cervical imaging and reading system)
- Participated in the Ministry of Health and Welfare’s “Cancer Conquest Project.”
2003
Digital system
- Developed the world’s first web-based cervical cancer screening system
2006
Dr. Cervicam Plus
- FDA and CE certification
- Selected as a World-class Product (Ministry of Trade, Industry and Energy)
2010
Dr. Cervicam Wifi
- Developed the world’s first wireless cervical imaging equipment
- Introduced the remote cervical cancer reading system
2019
Dr. Cervicam C20
- CMOS-based
- Supplied to more than 1,500 hospitals and clinics worldwide
2022
CerviCARE® AI
- AI Screening system
- Class 3 AI medical device approval by the Korea Ministry of Food and Drug Safety